Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

1 ML palivizumab 100 MG/ML Injection [Synagis]

Known as: PALIVIZUMAB 100 mg in 1 mL INTRAMUSCULAR INJECTION, SOLUTION [Synagis], Synagis 100 MG in 1 ML Injection, Synagis 100 MG per 1 ML Injection 
 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (2)

1 ML palivizumab 100 MG/ML Injectionpalivizumab Injection [Synagis]
Chloride IonGlycineHistidineInjection
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Intérêt microbiologique du palivizumab chez les nourrissons atteints de mucoviscidose : étude rétrospective, multicentrique, cas-témoins
Introduction Un lien entre les infections respiratoires par le virus respiratoire syncytial (VRS) et la primocolonisation precoce… Expand
2014
2014
138: Respiratory Illness and Respiratory Syncytial Virus Hospitalizations in Infants with Congenital Airway Anomalies in the Canadian Registry of Synagis® Following Prophylaxis (2005–2013)
 
2013
2013
Rsv Hospitalization In Infants With Neuromuscular Disease In The Canadian Registry Of Synagis® (Caress) Following Prophylaxis (2005-2012)
gastric cancer. Its acquisition is related with poor socioeconomic conditions while the relationship of nutrition and Hp is still… Expand
Review
2012
Review
2012
Targeting RSV with vaccines and small molecule drugs.
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a… Expand
2012
2012
263 RSV Hospitalization in Cystic Fibrosis in the Canadian Registry of Synagis® (Caress) following Prophylaxis (2005–2011)
Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus… Expand
Review
2011
Review
2011
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup…
BACKGROUND Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to… Expand
  • table 1
  • table 2
  • figure 1
  • table 4
  • figure 2
2004
2004
Prévention des infections à VRS par le palivizumab (Synagis®) chez les enfants atteints de cardiopathie congénitale. Recommandations de la Filiale de Cardiologie Pédiatrique de la Société Française…
Le palivizumab (Synagis®) a recu une autorisation d'emploi en France pour la prophylaxie des infections a VRS chez les… Expand
2004
2004
Quando indicar o palivizumab (Synagis®) na profilaxia da infecção do trato respiratório inferior pelo vírus sincicial respiratório?
 
2003
2003
SYNAGIS ® ( PALIVIZUMAB ) for Intramuscular Administration
  • SYNAGIS® PALIVIZUMAB
  • 2003
    • Corpus ID: 15935399
DESCRIPTION: Synagis® (palivizumab) is a humanized monoclonal antibody (IgG1κ ) produced by recombinant DNA technology, directed… Expand
Highly Cited
1998
Highly Cited
1998
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
Background.Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE